A new rating scale for Alzheimer's disease.

Wilma G. Rosen, Richard C. Mohs, Kenneth L. Davis · American Journal of Psychiatry · 1984

Summary

A new rating instrument, the Alzheimer's Disease Assessment Scale, was designed specifically to evaluate the severity of cognitive and noncognitive behavioral dysfunctions characteristic of persons with Alzheimer's disease.

Type: article
Published: 1984-11-01
Cited by: 4,293
References: 2
DOI: https://doi.org/10.1176/ajp.141.11.1356
PubMed: https://pubmed.ncbi.nlm.nih.gov/6496779/
OpenAlex: https://openalex.org/W1953027527
Semantic Scholar: https://api.semanticscholar.org/CorpusID:11664332

Keywords

References

Rating scales for geriatric psychopharmacology--a review.C Salzman, Gerald E. Kochansky, Richard I. Shader — 1972
RELIABILITY AND VALIDITY OF A SCALE FOR ASSESSING THE FUNCTIONING OF GERIATRIC PATIENTSRobert Plutchik, Hope R. Conte, Morris Lieberman — 1970
ALZHEIMERʼS DISEASEMyre Sim, ISRAEL SUSSMAN — 1962

Cited by

Emerging drugs for Alzheimer's disease. Mechanisms of action and prospects for cognitive enhancing medications.Lon S. Schneider, Pierre N. Tariot — 1994
POTENTIAL LONG‐TERM EFFECTS OF RIVASTIGMINE ON DISEASE PROGRESSION MAY BE LINKED TO DRUG EFFECTS ON VASCULAR CHANGES IN ALZHEIMER BRAINSTimo Erkinjuntti, Ingmar Skoog, Roger Lane — 2003
Rivastigmine in Alzheimer’s disease: Cognitive function and quality of lifeRoberta Annicchiarico, Alessia Federici, Carla Pettenati — 2007
[Diagnostic value and functional correlations of the ADAS-Cog scale in Alzheimer's disease: data on NORMACODEM project].A Monllau, J Pena-Casanova, Rafael Blesa — 2007
Plasma 3-methoxy-4-hydroxyphenylglycol (MHPG) and clinical symptoms in Alzheimer's disease.Javier Garmar, Carlos Reviriego — 1995
Estrogen Replacement Therapy for Treatment of Mild to Moderate Alzheimer DiseaseRuth A. Mulnard, Carl W. Cotman, Claudia H. Kawas — 2013
Metrifonate for Alzheimer's diseaseDavid S. Knopman — 1998
The Clinical Trial Protocol of the Metrifonate in ALzheimer’s Trial (MALT)冬樹伊藤 — 1998
Economic impact of Alzheimer's disease in the United KingdomXavier Pastor — 1999
Pharmacologic Management of Alzheimer Disease Part III: Nonsteroidal Antiinflammatory Drugs — Emerging Protective Evidence?许东升 — 1999
Cholinergic dysfunction in diseases with Lewy bodies김동희 — 2000
The Severe Cognitive Impairment Profile (SCIP)Luis Carro Sancristóbal — 2000
Neuroimaging in alzheimer’s disease: Relevance for treatmentFenger-Woźnicka Sławomira — 2001
Alpha-lipoic acid as a new treatment option for Alzheimer [corrected] type dementia.Laurette Sejourné — 2001
Brain donation in normal aging: procedures, motivations, and donor characteristics from the Biologically Resilient Adults in Neurological Studies (BRAiNS) Project.Aiko Yoshino — 2001
Influence of the Severity of Cognitive Impairment on the Effect of the Ginkgo biloba Extract EGb 761® in Alzheimer’s DiseaseBernhard Dotzler — 2002
Supplementation and the elderly: dramatic results?Jacques Massip — 2002
Successful Treatment of Behavioural Problems in Dementia Using a Cholinesterase Inhibitor: The Ethical Questions隆生数見 — 2002
Clinical Efficacy of Piracetam in Cognitive Impairment: A Meta-AnalysisCasimiro Cabrera-Abreu — 2002
Long-term effects of rivastigmine in moderately severe Alzheimer's disease: does early initiation of therapy offer sustained benefits?Nejmi Cengiz, Arif Salimov — 2002

A new rating scale for Alzheimer's disease.

Summary

Keywords

References

Cited by

Related papers